Does Gilead Sciences Stock Lead the Pack?
Gilead Sciences’ stock has outperformed many peers over the past year, but how does it measure up in a dynamic biopharma landscape as of January 27, 2026? GILD boasts strong operating and free cash flow margins. Yet, its revenue growth is moderate, and its valuation, while not extreme, is higher than some rivals. This indicates a robust core, but its upside may hinge on pipeline advancements in areas like HIV and oncology, crucial in the evolving industry.
- GILD has the highest operating margin among peers at 38.3%, reflecting strong profitability from its efficient HIV business and favorable product mix.
- GILD’s revenue growth of 2.8% in the last 12 months is low, lagging ABBV, PFE, JNJ but outpacing MRK, BMY, due to Veklury declines and HIV competition.
- GILD gained 52.0% in the past year, outperforming its peers, and currently trades at a PE of 21.6, driven by pipeline success and new HIV prevention approvals.
Here’s how Gilead Sciences stacks up across size, valuation, and profitability versus key peers.
| GILD | ABBV | MRK | BMY | PFE | JNJ | |
|---|---|---|---|---|---|---|
| Market Cap ($ Bil) | 175.2 | 396.1 | 269.3 | 113.1 | 150.7 | 540.5 |
| Revenue ($ Bil) | 29.1 | 59.6 | 64.2 | 48.0 | 62.8 | 92.1 |
| PE Ratio | 21.6 | 165.9 | 14.1 | 18.7 | 15.3 | 21.5 |
| LTM Revenue Growth | 2.8% | 7.4% | 1.7% | 1.3% | 3.9% | 5.1% |
| LTM Operating Margin | 38.3% | 24.1% | 34.9% | 23.8% | 24.6% | 26.2% |
| LTM FCF Margin | 31.5% | 33.0% | 20.3% | 31.9% | 16.5% | 20.3% |
| 12M Market Return | 52.0% | 30.8% | 14.3% | -3.7% | 5.8% | 51.3% |
For more details on Gilead Sciences, read Buy or Sell GILD Stock. Below we compare GILD’s growth, margin, and valuation with peers across years
Revenue Growth Comparison
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| GILD | 2.8% | 6.0% | -0.6% | -0.1% |
| ABBV | 7.4% | 3.7% | -6.4% | 3.3% |
| MRK | 1.7% | 6.7% | 1.4% | 21.7% |
| BMY | 1.3% | 7.3% | -2.5% | -0.5% |
| PFE | 3.9% | 6.8% | -41.1% | 24.5% |
| JNJ | 5.1% | 4.3% | 6.5% | 1.6% |
Operating Margin Comparison
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| GILD | 38.3% | 36.5% | 32.5% | 40.2% |
| ABBV | 24.1% | 21.1% | 24.9% | 32.4% |
| MRK | 34.9% | 31.5% | 4.9% | 30.8% |
| BMY | 23.8% | 12.2% | 18.2% | 19.7% |
| PFE | 24.6% | 23.3% | 7.1% | 36.7% |
| JNJ | 26.2% | 24.9% | 27.5% | 26.3% |
PE Ratio Comparison
| LTM | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| GILD | 21.6 | 318.9 | 20.3 | 22.1 |
| ABBV | 165.9 | 94.5 | 64.6 | 23.2 |
| MRK | 14.1 | 15.6 | 691.5 | 19.0 |
| BMY | 18.7 | -12.2 | 14.6 | 17.3 |
| PFE | 15.3 | 17.6 | 70.7 | 5.1 |
| JNJ | 21.5 | 35.4 | 10.4 | 22.9 |
Still not sure about GILD stock? Consider portfolio approach.
The Right Way To Invest Is Through Portfolios
Individual stocks are unpredictable. A smart portfolio keeps you invested, limits downside shocks, and provides upside exposure
The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.